10x Genomics (TXG) Stock Forecast & Price Target

Compare

1,224 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TXG Analyst Ratings

Moderate Buy

4 Buy

9 Hold

0 Sell

Based on 13 analysts giving stock ratings to

10x

Genomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TXG Stock 12 Month Forecast

Average Price Target

$19.67

▲(4.18% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $19.67 with a high forecast of $22.00 and a low forecast of $17.00. The average price target represents a 4.18% change from the last price of $18.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","11":"$11","15":"$15","19":"$19","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11,15,19,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.95,20.107692307692307,20.265384615384615,20.423076923076923,20.58076923076923,20.73846153846154,20.896153846153847,21.053846153846152,21.21153846153846,21.369230769230768,21.526923076923076,21.684615384615384,21.842307692307692,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.95,19.928461538461537,19.906923076923075,19.885384615384616,19.863846153846154,19.842307692307692,19.82076923076923,19.79923076923077,19.77769230769231,19.756153846153847,19.734615384615385,19.713076923076926,19.691538461538464,{"y":19.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.95,19.723076923076924,19.496153846153845,19.26923076923077,19.04230769230769,18.815384615384616,18.588461538461537,18.361538461538462,18.134615384615383,17.907692307692308,17.68076923076923,17.453846153846154,17.22692307692308,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 66, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 75, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.08,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 61, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 58, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$19.67

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luke Sergott

Barclays

$22

Buy

16.53%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and 10x Genomics (NASDAQ: TXG)

Dan Leonard

UBS

$14→$20

Hold

5.93%

Upside

Reiterated

02/19/26

UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)

Kallum Titchmarsh

Morgan Stanley

$20

Hold

5.93%

Upside

Reiterated

02/17/26

Analysts Are Neutral on Top Healthcare Stocks: 10x Genomics (TXG), Moderna (MRNA)

Daniel Brennan

TD Cowen

$18→$19

Hold

0.64%

Upside

Reiterated

02/13/26

Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside

Tycho Peterson

Jefferies

$21

Buy

11.23%

Upside

Reiterated

02/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (NASDAQ: VRTX) and 10x Genomics (NASDAQ: TXG)

David Westenberg

Piper Sandler

$19

Hold

0.64%

Upside

Reiterated

02/13/26

Piper Sandler Remains a Hold on 10x Genomics (TXG)

Michael Ryskin

Bank of America Securities

$18→$21

Hold

11.23%

Upside

Reiterated

02/13/26

Neutral on 10x Genomics: Solid Competitive Position but Cautious Spending and Unclear Growth Keep Rating at Hold

Kyle Mikson CFA

Canaccord Genuity

$22

Buy

16.53%

Upside

Reiterated

02/13/26

10x Genomics price target raised to $22 from $20 at Canaccord10x Genomics price target raised to $22 from $20 at Canaccord

Daniel Arias

Stifel Nicolaus

$15→$20

Buy

5.93%

Upside

Reiterated

02/13/26

10x Genomics price target raised to $20 from $15 at Stifel10x Genomics price target raised to $20 from $15 at Stifel

Justin Bowers

Deutsche Bank

$16→$17

Hold

-9.96%

Downside

Reiterated

02/13/26

10x Genomics price target raised to $17 from $16 at Deutsche Bank10x Genomics price target raised to $17 from $16 at Deutsche Bank

Matt Larew

William Blair

―

Hold

―

Assigned

02/13/26

We rate the stock Market Perform (full stock thoughts are in the note).

Casey Woodring

J.P. Morgan

$15→$17

Hold

-9.96%

Downside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), Humana (NYSE: HUM) and 10x Genomics (NASDAQ: TXG)

Patrick B Donnelly

Citi

$18

Hold

-4.66%

Downside

Reiterated

02/12/26

Analysts Conflicted on These Healthcare Names: 10x Genomics (NASDAQ: TXG), Viking Therapeutics (NASDAQ: VKTX) and Apogee Therapeutics (NASDAQ: APGE)

Puneet Souda

Leerink Partners

$15→$16

Hold

-15.25%

Downside

Reiterated

08/11/25

Leerink Partners Remains a Hold on 10x Genomics (TXG)

Subbu Nambi

Guggenheim

―

Hold

―

Reiterated

02/23/25

We expect TXG to share more on what these new products will mean for the research community and their competitive positioning at AGBT, especially given other updates from the likes of BRKR and ILMN heading into the conference. *** We will be attending AGBT in person. If you are there and want to meet, let us know. Also, please email us if you want to schedule a time to chat after.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luke Sergott

Barclays

$22

Buy

16.53%

Upside

Reiterated

02/20/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and 10x Genomics (NASDAQ: TXG)

Dan Leonard

UBS

$14→$20

Hold

5.93%

Upside

Reiterated

02/19/26

UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)

Kallum Titchmarsh

Morgan Stanley

$20

Hold

5.93%

Upside

Reiterated

02/17/26

Analysts Are Neutral on Top Healthcare Stocks: 10x Genomics (TXG), Moderna (MRNA)

Daniel Brennan

TD Cowen

$18→$19

Hold

0.64%

Upside

Reiterated

02/13/26

Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside

Tycho Peterson

Jefferies

$21

Buy

11.23%

Upside

Reiterated

02/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (NASDAQ: VRTX) and 10x Genomics (NASDAQ: TXG)

David Westenberg

Piper Sandler

$19

Hold

0.64%

Upside

Reiterated

02/13/26

Piper Sandler Remains a Hold on 10x Genomics (TXG)

Michael Ryskin

Bank of America Securities

$18→$21

Hold

11.23%

Upside

Reiterated

02/13/26

Neutral on 10x Genomics: Solid Competitive Position but Cautious Spending and Unclear Growth Keep Rating at Hold

Kyle Mikson CFA

Canaccord Genuity

$22

Buy

16.53%

Upside

Reiterated

02/13/26

10x Genomics price target raised to $22 from $20 at Canaccord10x Genomics price target raised to $22 from $20 at Canaccord

Daniel Arias

Stifel Nicolaus

$15→$20

Buy

5.93%

Upside

Reiterated

02/13/26

10x Genomics price target raised to $20 from $15 at Stifel10x Genomics price target raised to $20 from $15 at Stifel

Justin Bowers

Deutsche Bank

$16→$17

Hold

-9.96%

Downside

Reiterated

02/13/26

10x Genomics price target raised to $17 from $16 at Deutsche Bank10x Genomics price target raised to $17 from $16 at Deutsche Bank

Matt Larew

William Blair

―

Hold

―

Assigned

02/13/26

We rate the stock Market Perform (full stock thoughts are in the note).

Casey Woodring

J.P. Morgan

$15→$17

Hold

-9.96%

Downside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), Humana (NYSE: HUM) and 10x Genomics (NASDAQ: TXG)

Patrick B Donnelly

Citi

$18

Hold

-4.66%

Downside

Reiterated

02/12/26

Analysts Conflicted on These Healthcare Names: 10x Genomics (NASDAQ: TXG), Viking Therapeutics (NASDAQ: VKTX) and Apogee Therapeutics (NASDAQ: APGE)

Puneet Souda

Leerink Partners

$15→$16

Hold

-15.25%

Downside

Reiterated

08/11/25

Leerink Partners Remains a Hold on 10x Genomics (TXG)

Subbu Nambi

Guggenheim

―

Hold

―

Reiterated

02/23/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

3 Months

xxx

Success Rate

9/21 ratings generated profit

Average Return

-0.24%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -0.24% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

10/21 ratings generated profit

Average Return

-1.40%

reiterated a buy rating 10 days ago

Copying Daniel Arias's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -1.40% per trade.

2 Years

xxx

Success Rate

13/26 ratings generated profit

Average Return

+7.66%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +7.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TXG Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TXG has received 8 Buy Ratings, 58 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the past 3 months is 19.67.

Each month's total comprises the sum of three months' worth of ratings.

TXG Financial Forecast

TXG Earnings Forecast

Next quarter’s earnings estimate for TXG is -$0.27 with a range of -$0.41 to -$0.07. The previous quarter’s EPS was -$0.13. TXG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.

TXG Sales Forecast

Next quarter’s sales forecast for TXG is $146.22M with a range of $141.30M to $150.40M. The previous quarter’s sales results were $166.03M. TXG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.

TXG Stock Forecast FAQ

What is TXG’s average 12-month price target, according to analysts?

Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 19.67.

What is TXG’s upside potential, based on the analysts’ average price target?

10x Genomics Inc has 4.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TXG a Buy, Sell or Hold?

10x Genomics Inc has a consensus rating of Moderate Buy which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.

What is 10x Genomics Inc’s price target?

The average price target for 10x Genomics Inc is 19.67. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $17.00. The average price target represents 4.18% Increase from the current price of $18.88.

What do analysts say about 10x Genomics Inc?

10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of TXG?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

10x Genomics (TXG) Stock Forecast & Price Target

TXG Analyst Ratings

TXG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 10x Genomics

TXG Analyst Recommendation Trends

TXG Financial Forecast

TXG Earnings Forecast

TXG Sales Forecast

TXG Stock Forecast FAQ

Detailed List of Analyst Forecasts